Edition:
India

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

4.27USD
13 Sep 2019
Change (% chg)

-- (--)
Prev Close
$4.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
58,968
52-wk High
$4.95
52-wk Low
$2.79

Latest Key Developments (Source: Significant Developments)

Chromadex Q1 Loss Per Share $0.15
Friday, 10 May 2019 

May 9 (Reuters) - Chromadex Corp ::ORATION REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.15.Q1 SALES $10 MILLION VERSUS REFINITIV IBES ESTIMATE OF $9.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.EXPECTS TO BE CASH FLOW BREAKEVEN BY Q4 OF 2019 OR EARLY 2020..  Full Article

Chromadex Corporation Reports Q3 Sales Rose 33 Percent To $8.1 Million
Thursday, 8 Nov 2018 

Nov 7 (Reuters) - Chromadex Corp ::ORATION REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.16.Q3 SALES ROSE 33 PERCENT TO $8.1 MILLION.  Full Article

Chromadex, Dartmouth File Patent Infringement Lawsuit Against Elysium Health
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Chromadex Corp ::CHROMADEX AND DARTMOUTH COLLEGE FILE PATENT INFRINGEMENT LAWSUIT AGAINST ELYSIUM HEALTH.CHROMADEX - COMPLAINT ALLEGES ELYSIUM'S BASIS DIETARY SUPPLEMENT VIOLATES PATENTS.CHROMADEX - CO IS EXCLUSIVE LICENSEE TO COMMERCIALIZE PATENTS THAT COVER COMPOSITIONS CONTAINING ISOLATED NICOTINAMIDE RIBOSIDE HELD BY DARTMOUTH.  Full Article

Chromadex Announces Strategic Partnership With Jiangxi Government
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Chromadex Corp ::CHROMADEX ANNOUNCES STRATEGIC PARTNERSHIP FOR AGING RESEARCH WITH JIANGXI GOVERNMENT IN CHINA.CHROMADEX CORP - ANNOUNCED A STRATEGIC PARTNERSHIP WITH JIANGXI PROVINCIAL GOVERNMENT, PEOPLE'S REPUBLIC OF CHINA.  Full Article

Chromadex Corporation Q4 Loss Per Share $0.17
Friday, 9 Mar 2018 

March 8 (Reuters) - Chromadex Corp ::ORATION REPORTS 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.17.Q4 SALES ROSE 69 PERCENT TO $7.5 MILLION.Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION.QTRLY ADJUSTED EBITDA PER SHARE WAS A LOSS OF $0.10.  Full Article

Chromadex Chairman Stephen Allen Will Retire From The Board
Saturday, 17 Feb 2018 

Feb 16 (Reuters) - Chromadex Corp ::CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS.CHROMADEX CORP - ‍ ALLEN WILL NOT STAND FOR RE-ELECTION AS A DIRECTOR AT CHROMADEX'S 2018 ANNUAL MEETING IN JUNE​.  Full Article

ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln
Monday, 12 Feb 2018 

Feb 12 (Reuters) - ChromaDex Corp ::ORATION REPORTS PRELIMINARY 2017 RESULTS.SEES Q4 2017 REVENUE ABOUT $7.5 MILLION.SEES FY 2017 REVENUE ABOUT $21.2 MILLION.AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION.‍FOR FULL YEAR 2017, OPERATING LOSS FROM CONTINUING OPERATIONS IS EXPECTED TO BE IN A RANGE OF $16 MILLION TO $17 MILLION​.  Full Article

Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders
Friday, 15 Dec 2017 

Dec 14 (Reuters) - Chromadex Corp ::CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

ChromaDex Q3 loss per share $0.07 from continuing operations
Friday, 10 Nov 2017 

Nov 9 (Reuters) - ChromaDex Corp ::ChromaDex reports third quarter 2017 financial results.Q3 loss per share $0.07 from continuing operations.Q3 sales rose 55 percent to $6.1 million.  Full Article

Chromadex announces $23 mln private placement of common stock
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Chromadex Corp :Chromadex announces $23 million private placement of common stock.Chromadex Corp - in connection with investment, co agreed to sell 5.6 million shares of common stock at a per share price of $4.10​.Chromadex Corp - ‍net proceeds of investment expected to provide co added resources to accelerate plans related to nad+ in general, tru niagen in particular​.  Full Article